Search This Blog

Monday, June 29, 2020

United Therapeutics extends Lilly Adcirca deal three years

United Therapeutics (NASDAQ:UTHR) discloses that it has amended its exclusive license agreement with Eli Lilly (NYSE:LLY) related to the marketing and sale of Adcirca (tadalafil) in the U.S. for pulmonary hypertension.
The new deal extends the term three years through December 31, 2023 from the previous end date of year-end this year.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.